Back to Journals » International Journal of Nanomedicine » Volume 7

Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells

Authors Matsuo H, Yoshimoto N, Iijima M, Niimi T, Jung J , Jeong S, Choi EK, Sewaki T, Arakawa T, Kuroda S

Received 10 April 2012

Accepted for publication 14 May 2012

Published 3 July 2012 Volume 2012:7 Pages 3341—3350

DOI https://doi.org/10.2147/IJN.S32813

Review by Single anonymous peer review

Peer reviewer comments 3



Hidenori Matsuo,1 Nobuo Yoshimoto,1 Masumi Iijima,1 Tomoaki Niimi,1 Joohee Jung,2,3 Seong-Yun Jeong,3 Eun Kyung Choi,3,4 Tomomitsu Sewaki,5 Takeshi Arakawa,6,7 Shun’ichi Kuroda1

1Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Japan; 2College of Pharmacy, Duksung Women’s University, Seoul, South Korea; 3Institute for Innovative Cancer Research, ASAN Medical Center, Seoul, South Korea; 4Department of Radiation Oncology, University of Ulsan College of Medicine, Seoul, South Korea; 5GenoLac BL Corporation, Okinawa, Japan; 6COMB, Tropical Biosphere Research Center, 7Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan

Abstract: Dendritic cells (DCs) are key regulators of adaptive T-cell responses. By capturing exogenous antigens and presenting antigen-derived peptides via major histocompatibility complex molecules to naïve T cells, DCs induce antigen-specific immune responses in vivo. In order to induce effective host immune responses, active delivery of exogenous antigens to DCs is considered important for future vaccine development. We recently generated bionanocapsules (BNCs) consisting of hepatitis B virus surface antigens that mediate stringent in vivo cell targeting and efficient endosomal escape, and after the fusion with liposomes (LP) containing therapeutic materials, the BNC-LP complexes deliver them to human liver-derived tissues in vivo. BNCs were further modified to present the immunoglobulin G (IgG) Fc-interacting domain (Z domain) derived from Staphylococcus aureus protein A in tandem. When mixed with IgGs, modified BNCs (ZZ-BNCs) displayed the IgG Fv regions outwardly for efficient binding to antigens in an oriented-immobilization manner. Due to the affinity of the displayed IgGs, the IgG-ZZ-BNC complexes accumulated in specific cells and tissues in vitro and in vivo. After mixing ZZ-BNCs with antibodies against DCs, we used immunocytochemistry to examine which antibodies delivered ZZ-BNCs to mouse splenic DCs following intravenous injection of the ZZ-BNCs. ZZ-BNCs displaying anti-CD11c monoclonal antibodies (α-CD11c-ZZ-BNCs) were found to accumulate with approximately 62% of splenic DCs, and reside within some of them. After the fusion with liposomes containing antigens, the α-CD11c-ZZ-BNCs could elicit the respective antibodies more efficiently than other nontargeting control vaccines, suggesting that this DC-specific nanocarrier is promising for future vaccines.

Keywords: drug-delivery system, gene-delivery system, liposomes, protein A, vaccine, ZZ domain

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.